Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients

The Hematology Journal : the Official Journal of the European Haematology Association
J BladéE Montserrat

Abstract

Melphalan and prednisone (MP) has been the standard treatment for multiple myeloma (MM) for the last 30 years. Combination chemotherapy at conventional doses has not shown a significant prolongation of survival when compared to MP. There are few data comparing conventional chemotherapy at standard doses with conventional treatment at higher doses. We present the long-term outcome of 914 patients from two randomized trials comparing three different dose intensity regimens. From 1 January, 1985 to 31 December, 1989, 487 patients were randomized between MP (melphalan 9 mg/m(2) p.o. and prednisone 60 mg/m(2) days 1-4) and alternating VCMP (vincristine 1 mg i.v. on day 1, cyclophosphamide 500 mg/m(2) i.v. on day 1, melphalan 6 mg/m(2) p.o. on days 1-4, and prednisone 60 mg/m(2) on days 1-4) and VBAP (vincristine 1 mg i.v. on day 1, BCNU and doxorubicin 30 mg/m(2) i.v. each on day 1, and prednisone 60 mg/m(2) on days 1-4). From 1 January, 1990 to 31 May, 1994, 427 patients were randomized between VCMP/VBAP at the above detailed doses (VCMP/VBAP 'SD') and the same regimen increasing the doses of cyclophosphamide and doxorubicin from 500 to 1200 mg/m(2) and from 30 to 50 mg/m(2), respectively (VCMP/VBAP 'HD'). Increasing dose intensity...Continue Reading

Citations

Dec 10, 2013·Journal of Hematology & Oncology·Joshua KellnerZihai Li
Aug 4, 2006·Journal of the American Society of Nephrology : JASN·Stephen M Korbet, Melvin M Schwartz
Aug 10, 2007·British Journal of Haematology·Guy PrattPaul Moss
Jan 18, 2006·British Journal of Haematology·Alastair SmithUNKNOWN British Committee for Standards in Haematology
Nov 26, 2010·Annual Review of Medicine·Jacob LaubachKenneth Anderson
May 17, 2011·British Journal of Haematology·Jennifer M BirdUNKNOWN Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum
Apr 7, 2009·British Journal of Haematology·Sagar Lonial, Jamie Cavenagh
Nov 7, 2019·Health Technology Assessment : HTA·Mark T DraysonJanet A Dunn
Jun 1, 2010·American Journal of Hematology·Yasuo MoriTakanori Teshima
Aug 2, 2011·Expert Review of Hematology·Javier de la Rubia, Mónica Roig
Sep 24, 2004·International Journal of Cancer. Journal International Du Cancer·R García-SanzJ F San Miguel
Feb 20, 2010·Medical Oncology·Jacob P LaubachKenneth C Anderson
Nov 26, 2010·Bone Marrow Transplantation·G CookUNKNOWN British Society for Blood and Marrow Transplantation (BSBMT)
Feb 2, 2015·Journal of Translational Medicine·Nicole A DoudicanAmitabha Mazumder
Jun 6, 2008·Leukemia·M A DimopoulosH Ludwig
Dec 29, 2012·American Journal of Clinical Pathology·Elizabeth P Weinzierl, Daniel A Arber
Jul 20, 2005·Best Practice & Research. Clinical Haematology·Joan Bladé, Laura Rosiñol
Nov 13, 2007·Hematology/oncology Clinics of North America·Joan Bladé, Laura Rosiñol

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.